Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline.


Journal

Journal of clinical oncology : official journal of the American Society of Clinical Oncology
ISSN: 1527-7755
Titre abrégé: J Clin Oncol
Pays: United States
ID NLM: 8309333

Informations de publication

Date de publication:
10 05 2019
Historique:
pubmed: 2 4 2019
medline: 9 4 2020
entrez: 2 4 2019
Statut: ppublish

Résumé

To provide evidence-based recommendations on the treatment of multiple myeloma to practicing physicians and others. ASCO and Cancer Care Ontario convened an Expert Panel of medical oncology, surgery, radiation oncology, and advocacy experts to conduct a literature search, which included systematic reviews, meta-analyses, randomized controlled trials, and some phase II studies published from 2005 through 2018. Outcomes of interest included survival, progression-free survival, response rate, and quality of life. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations. The literature search identified 124 relevant studies to inform the evidence base for this guideline. Evidence-based recommendations were developed for patients with multiple myeloma who are transplantation eligible and those who are ineligible and for patients with relapsed or refractory disease.

Identifiants

pubmed: 30932732
doi: 10.1200/JCO.18.02096
doi:

Types de publication

Journal Article Practice Guideline

Langues

eng

Sous-ensembles de citation

IM

Pagination

1228-1263

Commentaires et corrections

Type : ErratumIn

Auteurs

Joseph Mikhael (J)

1 City of Hope Cancer Center, Phoenix, AZ.
2 International Myeloma Foundation, North Hollywood, CA.

Nofisat Ismaila (N)

3 American Society of Clinical Oncology, Alexandria VA.

Matthew C Cheung (MC)

4 Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.

Caitlin Costello (C)

5 UC San Diego Moores Cancer Center, La Jolla, CA.

Madhav V Dhodapkar (MV)

6 Emory University, Atlanta, GA.

Shaji Kumar (S)

7 Mayo Clinic, Rochester MN.

Martha Lacy (M)

7 Mayo Clinic, Rochester MN.

Brea Lipe (B)

8 University of Rochester Medical Center, Rochester, NY.

Richard F Little (RF)

9 National Cancer Institute, Bethesda, MD.

Anna Nikonova (A)

10 Juravinski Cancer Center, Hamilton, Ontario, Canada.

James Omel (J)

11 Education and Advocacy, Grand Island, NE.

Namrata Peswani (N)

12 Advocate Medical Group, Chicago, IL.

Anca Prica (A)

13 Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

Noopur Raje (N)

14 Massachusetts General Hospital, Boston, MA.

Rahul Seth (R)

15 Upstate Medical University, Syracuse, NY.

David H Vesole (DH)

16 Hackensack University Medical Center, Hackensack, NJ.
17 Georgetown University, Washington, DC.

Irwin Walker (I)

18 McMaster University, Hamilton, Ontario, Canada.

Alexander Whitley (A)

19 Central Alabama Radiation Oncology, Montgomery, AL.

Tanya M Wildes (TM)

20 Washington University Medical School, St Louis, MO.

Sandy W Wong (SW)

21 University of California San Francisco, San Francisco, CA.

Tom Martin (T)

21 University of California San Francisco, San Francisco, CA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH